Forest Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Forest Pharmaceuticals's estimated annual revenue is currently $75M per year.
- Forest Pharmaceuticals's estimated revenue per employee is $576,923
Employee Data
- Forest Pharmaceuticals has 130 Employees.
Forest Pharmaceuticals's People
Name | Title | Email/Phone |
---|
What Is Forest Pharmaceuticals?
Forest Pharmaceuticals, Inc. (FPI) – a wholly-owned subsidiary of Forest Laboratories, Inc. – manufactures, distributes, and sells Forest-branded ethical prescription products in the United States and Puerto Rico. Operating several manufacturing and packaging plants in Missouri and Ohio, FPI is headquartered just outside St. Louis on an expansive campus that is home to many of Forest's customer services and support, including our Professional Affairs center and Distribution hub. Forest's national sales force – the largest component of FPI – promotes our growing line of CNS and cardiovascular products to healthcare professionals. Innovative customer service strategies, state-of-the-art technology, and cross-disciplinary teamwork enable us to deliver our products quickly to those who need them most. We encourage talented, energetic, career-minded individuals to search the dynamic career opportunities available throughout Forest.
keywords:N/AN/A
Total Funding
130
Number of Employees
$75M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Forest Pharmaceuticals News
VetriScience Laboratories, Pure Encapsulations, Jilin Forest Industry, Thorne Research Inc., Vital Pharmaceuticals Lonza, Swanson Health...
... AC Immune, TauRx Pharmaceuticals Ltd., Actavis plc., Forest Laboratories, Teva Pharmaceuticals Industries Ltd., Janssen Pharmaceutical.
Alkermes, Allergan (Forest Labs)/ Geodon Ritcher, , AstraZeneca, Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals, Eli Lilly,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $13M | 130 | -10% | N/A |
#2 | $3.5M | 130 | 7% | N/A |
#3 | $13.1M | 131 | 8% | N/A |
#4 | $35.6M | 132 | 9% | N/A |
#5 | $33M | 132 | 8% | N/A |